COLUMBUS, Ohio – Researchers have developed two new anticancer peptide vaccines and two peptide inhibitors as part of a larger peptide immunotherapy effort at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James).
Two studies, published in the journal OncoImmunology, identify new peptide vaccines and inhibitors that target the HER-3 and IGF-1R receptors. All four agents elicited significant anti-tumor responses in human cancer cell lines and in animal models.